Media ReleasesImmutep

View All Immutep News

Immutep granted European patent for eftilagimod alpha

SYDNEY, AUSTRALIA – 23 May 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 3089749) entitled “Combined Preparations for the Treatment of Cancer” by the European Patent Office.

For further information please download PDF attached: 
Download this document